Hemostemix Inc V.HEM

Alternate Symbol(s): HMTXF

Healthcare Biotechnology

Hemostemix Inc. is a Canada-based autologous stem cell therapy company. The Company has developed, patented, and is scaling a patient’s blood-based stem cell therapeutics platform, which includes angiogenic cell precursors, neuronal cell precursors and cardiomyocyte cell precursors. The Company holds 87 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01, its lead clinical-stage candidate, is an autologous cell therapy for the treatment of critical limb ischemia. ACP-01 is in a Phase 2 clinical trial in Canada and the United States. Its technology includes methods for collecting the synergetic cell population and manufacturing a personalized regenerative therapy that can be administered to a patient within seven days of the initial cell collection. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd. and PreCerv Inc.

TSXV:HEM - Post by User

Hemostemix Inc

Bullboard Posts

Comment by kareadon Aug 02, 2011 10:36pm

211 Views

Post# 18897345

RE: Trimble 2Q11 (HEM Data Point)

dt_core hasn't been around long enough to realize this, but just because Trimble reports good numbers doesn't mean that HEM will. Sure does look like HEM is losing market share. Again.
Having said that, it won't take much of quarter to pacify people because expectations are probably pretty low. So is the share price.
But, then comes money losing Q3 and then maybe breakeven Q4. So, maybe the share price will go up in Q1 of 2012. Maybe.

Bullboard Posts

Morning Market Outlook for June 13, 2024